MedPlus Health Services Limited has announced a board meeting scheduled for May 29, 2026, to consider and approve the company's audited financial results for the fourth quarter and financial year ended March 31, 2026. The announcement was made through a formal communication to stock exchanges on March 28, 2026.

Board Meeting Details

The meeting has been scheduled in compliance with Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will review both standalone and consolidated financial results for the reporting period.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prevention of Insider Trading, MedPlus Health Services has implemented a trading window closure for designated persons.

Result Publication and Disclosure

Following the board meeting's conclusion, the company will submit the audited financial results to both BSE Limited and National Stock Exchange of India Limited. The results will be made available through multiple channels to ensure comprehensive disclosure to stakeholders.

The financial results will be:

• Submitted to stock exchanges after board meeting conclusion
• Hosted on the company's official website at www.medplusindia.com
• Published in newspapers as per SEBI LODR requirements
• Available on BSE and NSE websites at www.bseindia.com and www.nseindia.com respectively

Regulatory Compliance

The announcement demonstrates MedPlus Health Services' adherence to regulatory requirements and corporate governance standards. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the formal communication, ensuring proper documentation and compliance with listing obligations.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a wholly-owned subsidiary, received a drug license suspension order from Karnataka's drug control authorities.

Regulatory Action Details

The suspension order was issued by the Assistant Director, Drugs Control Administration, Hubli Circle, Hubli, Karnataka. The action specifically targets a store situated at Kalyan Nagar, Dharwad, Karnataka, with the suspension effective for three days.

Legal Framework and Violations

The suspension has been imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India.

Financial Impact Assessment

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of Rs 0.66 lacs due to the three-day suspension of operations at the affected store.

Compliance and Disclosure

The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in compliance with SEBI circulars dated July 13, 2023, and December 31, 2024. The information has been made available on the company's website and will also be accessible through BSE and NSE platforms.

This regulatory action represents a localized operational challenge for the pharmacy chain, affecting one store within its extensive retail network across multiple states.